transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Treatment of medullary thyroid cancer using a combination of radiation and gemcitabine

Författare och institution:
Viktor Sandblom (Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik); Johan Spetz (Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik); J Swanpalmer (-); Eva Forssell-Aronsson (Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik)
Publicerad i:
62nd Annual International Meeting Radiation Research Society 2016. Big Island, Hawaii, USA, October 16-19, 2016,
Publikationstyp:
Konferensbidrag - refereegranskat abstract
Publiceringsår:
2016
Språk:
engelska
Sammanfattning (abstract):
INTRODUCTION Medullary thyroid cancer (MTC) is a very rare type of cancer and patients often present with metastatic disease at the time of diagnosis. In contrast to other types of thyroid cancers, MTC originates from C-cells and therefore lacks the iodine pump NIS. This means that MTC cannot be treated with radioiodine, which otherwise is a common systemic treatment method for thyroid cancer. Instead, the use of radiolabelled somatostatin analogues (e.g. 177Lu-octreotate) might be an option, since many MTCs overexpress somatostatin receptors. Furthermore, the nucleoside analogue gemcitabine has previously been used to treat MTC. The aim of this study was to investigate potential synergistic effects of combining irradiation with gemcitabine for treatment of MTC. METHODS The patient-derived MTC cell line GOT2 was transplanted to BALB/c nude mice, which received radiation therapy alone, gemcitabine alone or a combination of both. Radiation therapy was given either as external beam radiotherapy or as i.v. injection of 177Lu-octreotate. The tumour volume was followed and compared with that in untreated mice. The radiation dose and the amount gemcitabine were chosen to give low treatment effect as single treatment to enable detection of any additive or synergistic effects. RESULTS Overall, the animals receiving a combination of both external beam radiotherapy and gemcitabine showed the largest reduction in tumour size over time. Both gemcitabine and external beam radiotherapy alone gave a clear detrimental effect on tumour growth compared with the control group, while the animals receiving only 177Lu-octreotate showed similar response as the control group, possibly due to a too low amount of injected activity. CONCLUSION The results indicate that an additive or even synergistic effect can be achieved by combining radiation with gemcitabine for treatment of MTC. Further studies should be made evaluating the full potential of combining gemcitabine with 177Lu-octreotate.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin ->
Cancer och onkologi
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin ->
Radiologi och bildbehandling ->
Radiofysik
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin ->
Radiologi och bildbehandling ->
Strålningsbiologi
Postens nummer:
237684
Posten skapad:
2016-06-14 13:31
Posten ändrad:
2016-06-28 09:58

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007